Ketohexokinase Inhibitor Improved Liver Health
A six-week study found that the drug PF-06835919 enhanced insulin sensitivity in patients with steatotic liver disease.
Updated on Oct. 7, 2026 in Weight Loss
Researchers have completed a randomized placebo-controlled crossover trial showing that the ketohexokinase inhibitor PF-06835919 improves insulin sensitivity. The treatment specifically targeted metabolic dysfunction-associated steatotic liver disease in patients.
Why it matters
High fructose consumption is a known contributor to cardiometabolic disease, making the development of targeted inhibitors a priority for medical researchers. This study offers new insight into how inhibiting ketohexokinase may mitigate liver-related metabolic issues.
The clinical trial included 15 participants over a 6-week treatment duration. The study successfully measured hepatic insulin sensitivity via insulin-stimulated suppression of endogenous glucose production.
The players
ClinicalTrials.gov
This is a web-based resource that provides patients, health care professionals, and the public with easy access to information on publicly and privately supported clinical studies.
The details
The drug PF-06835919 successfully reduced intrahepatic lipid and saturated fatty acid content during the study period. While the intervention improved glucose disposal and adjusted lipoprotein particle distribution, it did not produce changes in total body weight.
Timeline
The pharmacological inhibition treatment lasted for 6 weeks.
Health Landscape
This study follows the research tracking patterns established by the clinical research infrastructure of ClinicalTrials.gov. The findings represent a milestone in understanding how specific enzyme inhibition can modify liver-related metabolic processes.
This study provides new data on potential future treatments for metabolic dysfunction-associated steatotic liver disease. Patients should note that this remains an experimental intervention that does not currently impact clinical practice or body weight management.
The takeaway
While the inhibitor showed promise in improving insulin sensitivity and reducing liver fat, its lack of effect on body weight highlights the complex nature of metabolic diseases. Researchers continue to evaluate how such pharmacological interventions might fit into broader metabolic health strategies.
Further reading
For more information on metabolic health, visit the Weight Loss section.
More information
View the full ClinicalTrials.gov study record for additional details on the trial protocols.
Source note: This article includes information reported by Nature.
